Amedisys Inc (AMED) 52.33 $AMED Amedisys: Home Health,

New Post Public Reply Private Reply Replies (0) Message Board

Jul 11, 2016 at 5:09 AM

Amedisys Inc (AMED) 52.33 $AMED

Amedisys: Home Health, Hospice Solid, Reimbursement Worries
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 7:07AM CDT
On Jul 7, 2016, we issued an updated research report on Baton Rouge, LA-based Amedisys Inc. (AMED).
USPH: 62.25 (+0.89), LHCG: 45.53 (+1.15), AAC: 22.65 (-0.12), AMED: 52.33 (+0.63)

Amedisys Brings In David B. Pearce As New Chief Compliance Officer
GlobeNewswire - Fri Jun 17, 7:00AM CDT
David B. Pearce will join Amedisys, Inc. (NASDAQ:AMED), as Senior Vice President and Chief Compliance Officer, effective July 5.
AMED: 52.33 (+0.63)

38.5% Return Seen to Date on SmarTrend Amedisys Call (AMED)
Comtex SmarTrend(R) - Mon Jun 13, 1:09PM CDT
SmarTrend identified an Uptrend for Amedisys (NASDAQ:AMED) on February 16th, 2016 at $36.58. In approximately 4 months, Amedisys has returned 38.55% as of today's recent price of $50.68.
AMED: 52.33 (+0.63)

Shares of AMED Up 43.1% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Jun 03, 12:51PM CDT
SmarTrend identified an Uptrend for Amedisys (NASDAQ:AMED) on February 16th, 2016 at $36.58. In approximately 4 months, Amedisys has returned 43.12% as of today's recent price of $52.36.
AMED: 52.33 (+0.63)

Amedisys to Present at the Jefferies 2016 Healthcare Conference
GlobeNewswire - Wed Jun 01, 3:00PM CDT
Amedisys, Inc. (NASDAQ:AMED), one of America's leading healthcare at home companies, today announced that Paul B. Kusserow, President and Chief Executive Officer, will present at the Jefferies 2016 Healthcare Conference in New York, NY on Wednesday, June 8, 2016.
AMED: 52.33 (+0.63)

Uptrend Call Working As Amedisys Stock Rises 39.9% (AMED)
Comtex SmarTrend(R) - Fri May 27, 12:30AM CDT
SmarTrend identified an Uptrend for Amedisys (NASDAQ:AMED) on February 16th, 2016 at $36.58. In approximately 3 months, Amedisys has returned 39.94% as of today's recent price of $51.19.
AMED: 52.33 (+0.63)

Amedisys Has Returned 37.8% Since SmarTrend Recommendation (AMED)
Comtex SmarTrend(R) - Thu May 19, 12:56PM CDT
SmarTrend identified an Uptrend for Amedisys (NASDAQ:AMED) on February 16th, 2016 at $36.58. In approximately 3 months, Amedisys has returned 37.75% as of today's recent price of $50.39.
AMED: 52.33 (+0.63)

Amedisys Up 40.8% Since SmarTrend Uptrend Call (AMED)
Comtex SmarTrend(R) - Thu May 12, 12:26AM CDT
SmarTrend identified an Uptrend for Amedisys (NASDAQ:AMED) on February 16th, 2016 at $36.58. In approximately 3 months, Amedisys has returned 40.76% as of today's recent price of $51.49.
AMED: 52.33 (+0.63)

Amedisys to Present at the Bank of America Merrill Lynch Health Care Conference
GlobeNewswire - Fri May 06, 9:00AM CDT
Amedisys, Inc. (NASDAQ:AMED), one of America's leading healthcare at home companies, today announced that Paul B. Kusserow, President and Chief Executive Officer, will present at the 2016 Bank of America Merrill Lynch Health Care Conference in Las Vegas, NV on Tuesday, May 10, 2016.
AMED: 52.33 (+0.63)

Amedisys (AMED) Lags Q1 Earnings, Revenues Top the Mark
Zacks Equity Research - Zacks Investment Research - Fri May 06, 8:56AM CDT
Amedisys Inc. (AMED) reported adjusted earnings from continuing operations of 33 cents per share in the first quarter of 2016.
BSX: 23.90 (+0.24), AFAM: 44.39 (+0.08), AMED: 52.33 (+0.63), HLS: 39.73 (+0.40)

Amedisys Reports First Quarter Financial Results
GlobeNewswire - Tue May 03, 4:31PM CDT
Amedisys, Inc. (NASDAQ:AMED), a leading home health and hospice company, today reported its financial results for the three-month period ended March 31, 2016.
AMED: 52.33 (+0.63)

Chemed (CHE) Q1 Earnings Miss the Mark, Revenues in Line
Zacks Equity Research - Zacks Investment Research - Mon May 02, 9:53AM CDT
Chemed Corp. (CHE) reported first-quarter 2016 adjusted earnings per share (EPS) of $1.53.
CHE: 137.48 (+2.22), AFAM: 44.39 (+0.08), AMED: 52.33 (+0.63), HLS: 39.73 (+0.40)

Amedisys Shares Up 42.1% Since SmarTrend's Buy Recommendation (AMED)
Comtex SmarTrend(R) - Wed Apr 27, 12:19AM CDT
SmarTrend identified an Uptrend for Amedisys (NASDAQ:AMED) on February 16th, 2016 at $36.58. In approximately 2 months, Amedisys has returned 42.13% as of today's recent price of $51.99.
AMED: 52.33 (+0.63)

Amedisys Announces First Quarter Earnings Release and Conference Call Date
GlobeNewswire - Tue Apr 26, 3:03PM CDT
Amedisys, Inc. (NASDAQ:AMED), one of America's leading home health and hospice care companies, announced today that it will report results for the first quarter ended March 31, 2016 after the market closes on May 3, 2016. The Company will host an investor conference call to discuss these results at 11:00 a.m. ET on May 4, 2016.
AMED: 52.33 (+0.63)

Amedisys Welcomes Three New Members To Its Board Of Directors
GlobeNewswire - Tue Apr 26, 8:00AM CDT
Amedisys Inc. (NASDAQ:AMED), a leading home health, hospice and personal care company, today announced the addition of three new members to its Board of Directors.
KND: 12.22 (+0.47), SYBT: 28.02 (+0.45), AMED: 52.33 (+0.63)

Quest Diagnostics (DGX) Q1 Earnings in Line, Volume Up
Zacks Equity Research - Zacks Investment Research - Thu Apr 21, 8:23AM CDT
Quest Diagnostics' (DGX) first-quarter 2016 adjusted earnings per share (EPS) of $1.12 came in line with the Zacks Consensus Estimate.
BSX: 23.90 (+0.24), AFAM: 44.39 (+0.08), DGX: 82.23 (+1.00), AMED: 52.33 (+0.63)

AmSurg Poised on Strategic Buyouts, Rising Costs a Concern
Zacks Equity Research - Zacks Investment Research - Wed Apr 20, 4:46PM CDT
On Apr 18, 2016, we issued an updated research report on Nashville, TN-based AmSurg Corp. (AMSG).
AMSG: 78.66 (+2.26), BSX: 23.90 (+0.24), AFAM: 44.39 (+0.08), AMED: 52.33 (+0.63)

Moving Average Crossover Alert: Amedisys (AMED)
Zacks Equity Research - Zacks Investment Research - Mon Apr 18, 9:11AM CDT
Amedisys Inc. (AMED) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front
AMED: 52.33 (+0.63)

Amedisys Shares Up 29.0% Since SmarTrend's Buy Recommendation (AMED)
Comtex SmarTrend(R) - Tue Apr 12, 1:43PM CDT
SmarTrend identified an Uptrend for Amedisys (NASDAQ:AMED) on February 16th, 2016 at $36.58. In approximately 2 months, Amedisys has returned 28.95% as of today's recent price of $47.17.
AMED: 52.33 (+0.63)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Food Trends Tease: 2027 sofi™ Awards' 75 Finalists

The Specialty Food Scene Heats Up Today’s world doesn’t rest when it comes to innovation, and the same goes for the tantalizing realm of specialty foods. Hot off the press, the Specialty Food Association (SFA) just rolled out the red carpet for its 75 finalists in the 2027 sofi™ Awards. These are the future taste shapers set to take center stage at the Winter...

Kansai Medical Ushers in New Era of Cancer Research

Breaking Ground in Cancer Treatment Trials I've seen some thrilling breakthroughs in my time following the pharmaceutical industry, but what Kansai Medical University and Daiichi Sankyo are doing elevates the game. They're rolling out the first patient dose of DS1025 in Osaka, Japan—a move that marks the onset of a global Phase 1 clinical trial. This is no ordinary...

Standex's New Financial Lead: Stoddard Takes Helm

New Financial Captain Aboard Standex's Ship Alright, here's something that'll have investors nodding along with interest: Standex International has just named Samantha L. Stoddard as their incoming Chief Financial Officer and Treasurer, effective December 1, 2026. Now, Standex isn't some scrappy upstart. We're talking about a veteran manufacturer intricately working...

Baidu Faces Class Action: Investors Push Against Fraud Allegations

Baidu Under Fire for Alleged Misleading Statements Here's a fresh slice of drama straight outta the corporate trenches: Baidu, Inc. (NASDAQ: BIDU) finds itself tangled in a securities fraud lawsuit that’s causing a ruckus across investor circles. Schall, Brown & Schwartz LLP, those heavyweight gladiators in shareholder rights, are calling on grieved investors to step up...

Encompass Health: Leader in Rehabilitation Again in 2026

Pinnacle of Rehab: Encompass Health's Notable Streak You know, in a world where healthcare accolades fly around like confetti, Encompass Health Corp's persistence in being named America's Most Awarded Leader in Inpatient Rehabilitation by Newsweek for the seventh straight year is something to chew on. The fact that a record 78 of its hospitals dotted across 32 states...

FLUX 3 Max Launches with Unmatched Speed and Quality

A Lightning Fast Leap in Video Generation It's all eyes on FLUX 3 Max today. You can almost hear the gasps of 'wow' in the generative media crowd. Why? Because this new weapon in the video gen arsenal, dreamed up by fal and Black Forest Labs, is slicing through the old speed limits like a blistering comet. Now, don't get me wrong. Seeds don't grow overnight, and neither...

GELITA Showcases Collagen Innovations at SupplySide 2026

Collagen Solutions Front and Center First up, a little chat about collagen might be in order. For folks not tied into the science side, it sounds like a trendy wellness potion. But here comes GELITA at SupplySide Global 2026, showing it's the real McCoy. Nestled in Booth #4565, they're laying out a spread of next-gen collagen innovations aimed at everything from wound...

TilePix Expands into Walmart with Nail-Free Decor Launch

TilePix Makes Big Moves with Walmart TilePix is launching their new line of nail-free wall décor at Walmart—this ain’t your grandma’s wall art. This company's bringing their magnetic, nail-free wizardry to retail stores nationwide for the first time, and they’ve chosen a real heavyweight partner—Walmart. What comes in the package? Well, they’re dealing in...

Steel Dynamics' Q3 2026: Record Shipments Boost Profits

Steel Dynamics Shatters Records in Q3 2026 If there was any doubt about Steel Dynamics' ability to ride the waves in the steel and aluminum market, the third quarter of 2026 put that to rest. With a record-breaking 3.8 million tons of steel shipped and net sales reaching a steep $6.5 billion, this isn't just business as usual—it's smashing their own ceiling. Operating...

Kenneth Smith Takes Helm for Trends Int’l Expansion

Tired of the Same Old Leadership Shuffle? Here Comes Kenneth Smith Look, I’ve seen my share of execs come and go, usually dragging the same old briefcase of stale ideas. But Kenneth Smith stepping up as CEO of Trends International? Now that’s got some real teeth to it. Come May 2026, he’s the guy at the helm, and he's got one hell of a to-do list. Smith's Roadmap: A...